company background image
ORTX

Orchard TherapeuticsNasdaqGS:ORTX Stock Report

Last Price

US$1.05

Market Cap

US$131.8m

7D

-16.0%

1Y

-83.8%

Updated

19 Jan, 2022

Data

Company Financials +
ORTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ORTX Stock Overview

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Orchard Therapeutics
Historical stock prices
Current Share PriceUS$1.05
52 Week HighUS$9.08
52 Week LowUS$1.04
Beta1.11
1 Month Change-16.00%
3 Month Change-48.53%
1 Year Change-83.85%
3 Year Change-91.43%
5 Year Changen/a
Change since IPO-92.50%

Recent News & Updates

Shareholder Returns

ORTXUS BiotechsUS Market
7D-16.0%-6.2%-4.6%
1Y-83.8%-19.8%7.7%

Return vs Industry: ORTX underperformed the US Biotechs industry which returned -18.4% over the past year.

Return vs Market: ORTX underperformed the US Market which returned 10.2% over the past year.

Price Volatility

Is ORTX's price volatile compared to industry and market?
ORTX volatility
ORTX Average Weekly Movement10.6%
Biotechs Industry Average Movement10.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: ORTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ORTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015224Bobby Gasparhttps://www.orchard-tx.com

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified cellular drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID).

Orchard Therapeutics Fundamentals Summary

How do Orchard Therapeutics's earnings and revenue compare to its market cap?
ORTX fundamental statistics
Market CapUS$131.77m
Earnings (TTM)-US$141.86m
Revenue (TTM)US$1.19m

110.6x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORTX income statement (TTM)
RevenueUS$1.19m
Cost of Revenue-US$476.00k
Gross ProfitUS$1.67m
ExpensesUS$143.52m
Earnings-US$141.86m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.13
Gross Margin139.93%
Net Profit Margin-11,900.67%
Debt/Equity Ratio13.6%

How did ORTX perform over the long term?

See historical performance and comparison

Valuation

Is Orchard Therapeutics undervalued compared to its fair value and its price relative to the market?

0.55x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ORTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORTX is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2.1x).


Future Growth

How is Orchard Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

23.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORTX's revenue (60.4% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: ORTX's revenue (60.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORTX is forecast to be unprofitable in 3 years.


Past Performance

How has Orchard Therapeutics performed over the past 5 years?

-10.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORTX is currently unprofitable.

Growing Profit Margin: ORTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORTX is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare ORTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ORTX has a negative Return on Equity (-58.79%), as it is currently unprofitable.


Financial Health

How is Orchard Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ORTX's short term assets ($291.5M) exceed its short term liabilities ($44.2M).

Long Term Liabilities: ORTX's short term assets ($291.5M) exceed its long term liabilities ($70.1M).


Debt to Equity History and Analysis

Debt Level: ORTX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ORTX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ORTX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24% each year.


Dividend

What is Orchard Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Bobby Gaspar (56 yo)

1.83yrs

Tenure

US$3,783,020

Compensation

Dr. Bobby Gaspar, M.D., Ph.D. has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a Director at Alliance for Reg...


CEO Compensation Analysis

Compensation vs Market: Bobby's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD579.29K).

Compensation vs Earnings: Bobby's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ORTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: ORTX's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.


Top Shareholders

Company Information

Orchard Therapeutics plc's employee growth, exchange listings and data sources


Key Information

  • Name: Orchard Therapeutics plc
  • Ticker: ORTX
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$131.774m
  • Shares outstanding: 125.50m
  • Website: https://www.orchard-tx.com

Number of Employees


Location

  • Orchard Therapeutics plc
  • 108 Cannon Street
  • London
  • Greater London
  • EC4N 6EU
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:50
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.